- Home
- AXSM vs GBDC Comparison
AXSM vs GBDC Comparison
Compare AXSM & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXSM
- GBDC
- Stock Information
- Founded
- AXSM 2012
- GBDC 2009
- Country
- AXSM United States
- GBDC United States
- Employees
- AXSM N/A
- GBDC N/A
- Industry
- AXSM Biotechnology: Pharmaceutical Preparations
- GBDC Finance: Consumer Services
- Sector
- AXSM Health Care
- GBDC Finance
- Exchange
- AXSM Nasdaq
- GBDC Nasdaq
- Market Cap
- AXSM 4.0B
- GBDC 4.0B
- IPO Year
- AXSM 2015
- GBDC 2010
- Fundamental
- Price
- AXSM $92.28
- GBDC $14.67
- Analyst Decision
- AXSM Strong Buy
- GBDC Buy
- Analyst Count
- AXSM 14
- GBDC 7
- Target Price
- AXSM $124.57
- GBDC $16.36
- AVG Volume (30 Days)
- AXSM 416.4K
- GBDC 1.5M
- Earning Date
- AXSM 11-04-2024
- GBDC 08-05-2024
- Dividend Yield
- AXSM N/A
- GBDC 7.90%
- EPS Growth
- AXSM N/A
- GBDC 63.15
- EPS
- AXSM N/A
- GBDC 1.58
- Revenue
- AXSM $291,489,000.00
- GBDC $664,811,000.00
- Revenue This Year
- AXSM $42.50
- GBDC $24.23
- Revenue Next Year
- AXSM $69.28
- GBDC $23.67
- P/E Ratio
- AXSM N/A
- GBDC $9.30
- Revenue Growth
- AXSM 59.73
- GBDC 19.10
- 52 Week Low
- AXSM $55.02
- GBDC $13.95
- 52 Week High
- AXSM $98.40
- GBDC $17.72
- Technical
- Relative Strength Index (RSI)
- AXSM 59.26
- GBDC 36.87
- Support Level
- AXSM $91.52
- GBDC $14.69
- Resistance Level
- AXSM $96.56
- GBDC $15.04
- Average True Range (ATR)
- AXSM 2.83
- GBDC 0.17
- MACD
- AXSM 0.20
- GBDC -0.01
- Stochastic Oscillator
- AXSM 54.60
- GBDC 0.53
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About GBDC Golub Capital BDC Inc.
Golub Capital BDC Inc is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in United States middle-market companies. It also invests in the second lien and subordinated loans, warrants, and minority equity securities in United States middle-market companies. The company generally invests in securities that have been rated below investment grade by independent rating agencies or that would be rated below investment grade if they were rated.